Zerve AI has secured a US$7.6 million seed funding round led by Paladin Capital Group
A US$7.6 million seed funding round, led by Paladin Capital Group, has been secured by Zerve AI.
Zerve AI has developed an end-to-end platform which leverages AI to simplify the building, management and deployment of data workflows. The platform is designed specifically for code-first data teams. Headquartered in Limerick, Ireland, Zerve AI was founded in 2021 by Jason Hillary, Greg Michaelson and Phily Hayes.
Paladin is a global investor that supports and accelerates the growth of innovative companies through venture investment, expansion and growth capital. The company is headquartered in Washington, DC, with offices in New York City, Silicon Valley, London and Luxembourg.
Oaklins’ team in Ireland acted as the sole financial advisor in this transaction.


Talk to the deal team
Related deals
BodhiCedric has acquired Network Media from Jellysmack
The media holding company BodhiCedric has acquired Network Media, an innovator in the creator economy, from Jellysmack, the global creator company.
Learn moreCustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions
Bengaluru-based SaaS firm Perfios Software Solutions Private Ltd. has acquired 100% of the equity shares in the fraud-detection platform CustomerXPs Software Private Ltd. (Clari5) for an undisclosed amount, enhancing its anti-financial crime management suite for financial institutions.
Learn moreBayer AG has entered into a takeover agreement with Cara Care
Bayer AG, renowned for its advancements in healthcare and life sciences, has finalized the acquisition of Cara Care (HiDoc Technologies GmbH), which entered debtor-in-possession proceedings in October 2024. Cara Care, an innovative digital health platform and official DiGA, aligns perfectly with Bayer’s strategic focus on digital health and the expansion of its innovative solutions portfolio. The transaction is expected to close in Spring 2025.
Learn more